Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). Over the past several years, a variety of treatments have shown evidence of benefit in SSc-ILD, including nintedanib, now approved by the FDA for the treatment of SSc-ILD. These advances have made effective screening and monitoring for SSc-ILD imperative to enable timely referral for treatment. In this timely session, Dr. Anna-Maria Hoffmann-Vold will review data supporting screening strategies for SSc-ILD, including pulmonary function tests and high-resolution CT scanning of the chest, and how these may be effectively employed to both screen and monitor patients and determine those with more severe and/or more progressive disease. Dr. Richard Silver will review the data supporting different medications being used to treat SSc-ILD, and suggest approaches for treatment of the individual patient.